p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis

Miao,Wang; Liu,Xiaodong; Wang,Hongqin; Fan,Yimin; Lian,Shizhong; Yang,Xin; Wang,Xinxing; Guo,Geng; Li,Qichao; Wang,Sifei

doi:10.3892/mmr.2015.3255

p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis

Authors:
- Wang Miao
- Xiaodong Liu
- Hongqin Wang
- Yimin Fan
- Shizhong Lian
- Xin Yang
- Xinxing Wang
- Geng Guo
- Qichao Li
- Sifei Wang
View Affiliations

Affiliations: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Radiotherapy, Shanxi Dayi Hospital, Taiyuan, Shanxi 030032, P.R. China
Published online on: January 26, 2015 https://doi.org/10.3892/mmr.2015.3255
Pages: 4165-4173
Copyright: © Miao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant glioma is a highly aggressive brain tumor with a poor prognosis. Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome. Growing evidence supports the concept that initial and recurrent GBM may derive from glioblastoma stem cells, which may be responsible for drug resistance. However, the molecular mechanisms underlying this resistance remain to be elucidated. In the present study, a TMZ‑resistant GBM cell line, U251R, was developed and subsequently divided into two subpopulations according to the CD133 immunophenotype. No significant difference was identified in the expression of O6‑methylguanine‑DNA‑methyltransferase (MGMT) between CD133+ U251R cells and CD133‑ U251R cells, whereas the CD133+ cell population was more resistant to TMZ‑induced growth inhibition and cell death. TMZ achieves its cytotoxic effect by inducing DNA lesions and p53 upregulated modulator of apoptosis (PUMA) is an essential mediator of DNA damage‑induced apoptosis independently of p53 status. Therefore, whether PUMA effectively enhances growth suppression and induces apoptosis when combined with TMZ was investigated. Consequently, it was found that adenoviruses expressing wild‑type‑PUMA not only lead to the apoptosis of CD133+ U251R cells alone, but also significantly increase their sensitivity toward TMZ by elevating the Bcl‑2‑associated X protein/B‑cell lymphoma‑2 ratio without alterations in MGMT expression. Therefore, PUMA may be a suitable target for intervention to improve the therapeutic efﬁcacy of TMZ.

View Figures

View References

1	Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
2	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: a clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 25:4127–4136. 2007. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
5	Pegg AE: Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 462:83–100. 2000. View Article : Google Scholar : PubMed/NCBI
6	Roos WP and Kaina B: DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar
7	Kaina B, Christmann M, Naumann S and Roos WP: MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 6:1079–1099. 2007. View Article : Google Scholar
8	Sabharwal A and Middleton MR: Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol. 6:355–363. 2006. View Article : Google Scholar : PubMed/NCBI
9	Day RS III, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, et al: Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature. 288:724–7. 1980. View Article : Google Scholar : PubMed/NCBI
10	Kondo N, Takahashi A, Ono K and Ohnishi T: DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids. 2010:5435312010. View Article : Google Scholar : PubMed/NCBI
11	Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, et al: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 12:4523–4532. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, et al: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI
13	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
14	Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007. View Article : Google Scholar
15	Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
16	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, et al: Notch promotes radioresistance of glioma stem cells. Stem Cells. 28:17–28. 2010.
18	Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, et al: Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 72:4119–4129. 2012. View Article : Google Scholar : PubMed/NCBI
19	Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, et al: Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain. 134:1331–1343. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kang MK and Kang SK: Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
21	Bleau AM, Huse JT and Holland EC: The ABCG2 resistance network of glioblastoma. Cell Cycle. 8:2936–2944. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
23	Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
24	Martinez-Rivera M and Siddik ZH: Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol. 83:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
25	Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 7:673–682. 2001. View Article : Google Scholar : PubMed/NCBI
26	Yu J and Zhang L: PUMA, a potent killer with or without p53. Oncogene. 27(Suppl 1): S71–S83. 2001. View Article : Google Scholar
27	Ito H, Kanzawa T, Miyoshi T, Hirohata S, Kyo S, et al: Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther. 16:685–698. 2005. View Article : Google Scholar : PubMed/NCBI
28	Nagane M, Kobayashi K, Ohnishi A, Shimizu S and Shiokawa Y: Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 37:897–906. 2007. View Article : Google Scholar : PubMed/NCBI
29	He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998. View Article : Google Scholar : PubMed/NCBI
30	Mukai S, Kondo Y, Koga S, Komata T, Barna BP, et al: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60:4461–4467. 2000.PubMed/NCBI
31	Villano JL, Seery TE and Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 64:647–655. 2009. View Article : Google Scholar : PubMed/NCBI
32	Beier D, Schulz JB and Beier CP: Chemoresistance of glio-blastoma cancer stem cells - much more complex than expected. Mol Cancer. 10:1282008. View Article : Google Scholar
33	Koritzer J, Boxhammer V, Schafer A, Shimizu T, Klampfl TG, et al: Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. PLoS One. 8:e644982013. View Article : Google Scholar : PubMed/NCBI
34	Francipane MG, Chandler J and Lagasse E: Cancer stem cells: A moving target. Curr Pathobiol Rep. 1:111–118. 2013. View Article : Google Scholar : PubMed/NCBI
35	Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol. 15:338–344. 2013. View Article : Google Scholar : PubMed/NCBI
36	Smith ND, Rubenstein JN, Eggener SE and Kozlowski JM: The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 169:1219–1228. 2003. View Article : Google Scholar : PubMed/NCBI
37	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
38	Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
39	Goh AM, Coffill CR and Lane DP: The role of mutant p53 in human cancer. J Pathol. 223:116–126. 2011. View Article : Google Scholar
40	Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
41	Oren M and Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2:a0011072010. View Article : Google Scholar : PubMed/NCBI
42	Haupt S, Berger M, Goldberg Z and Haupt Y: Apoptosis - the p53 network. J Cell Sci. 116:4077–4085. 2003. View Article : Google Scholar : PubMed/NCBI
43	Yu J, Yue W, Wu B and Zhang L: PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res. 12:2928–2936. 2006. View Article : Google Scholar : PubMed/NCBI
44	Ma J, Murphy M, O’Dwyer PJ, Berman E, Reed K, et al: Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol. 63:1219–1228. 2002. View Article : Google Scholar : PubMed/NCBI
45	Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, et al: The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 66:2757–2764. 2006. View Article : Google Scholar : PubMed/NCBI
46	Tothova E, Fricova M, Stecova N, Kafkova A and Elbertova A: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma. 49:141–144. 2002.PubMed/NCBI
47	Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, et al: Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
48	Eisele G and Weller M: Targeting apoptosis pathways in glioblastoma. Cancer Lett. 332:335–345. 2013. View Article : Google Scholar